Avidity Partners Management’s Immuneering IMRX Stock Holding History

Avidity Partners Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-90,900	Closed	-$636K	–	48
2025 Q3	$636K	Buy	+90,900	New	+$472K	0.14%	43

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avidity Partners Management's IMRX Position: Q4 2025 in Review

Avidity Partners Management sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 90,900 shares — an estimated $636K sold.

Avidity Partners Management first reported a position in IMRX in Q3 2025 and held it in 1 quarter. The position peaked at $636K in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

Avidity Partners Management reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
Avidity Partners Management sold 90,900 Immuneering shares in Q4 2025, an estimated $636K.
Avidity Partners Management first reported a position in Immuneering in Q3 2025 and held it in 1 quarter.
Avidity Partners Management's Immuneering position peaked at $636K in Q3 2025.
86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.